The AdvancedGx Pharmacogenomics (PGx) Program is a clinically disciplined, end-to-end PGx solution purpose-built for self-funded health plans, Taft-Hartley funds, and employer groups.Advanced Laboratory Services, Inc (ALSI) operates its own CLIA-certified, CAP-accredited laboratory, maintaining direct oversight of testing quality, turnaround time, and reporting standards. The AdvancedGx panel is purpose-built for the health benefits market, covering drug classes that drive the greatest clinical and financial risk in self-funded populations — including behavioral health, cardiovascular, pain management, anticoagulation, and biologics. Reporting is limited to high-confidence drug-gene interactions per FDA, CPIC, PharmGKB, and DPWG guidelines, reducing clinical ambiguity and fiduciary risk for plan sponsors.ALSI applies a proprietary risk-stratification algorithm to pharmacy and medical claims data to identify members most likely to have actionable results, concentrating program investment where ROI potential is highest.Following testing, each result is reviewed by a PGx-trained clinical pharmacist who delivers a personalized member consultation and a provider-directed Medication Action Plan — designed to help ensure that genetic findings inform actual prescribing decisions.Ongoing population monitoring flags newly identified members and first-fill events on drug-gene interaction medications, extending clinical value beyond initial enrollment.
Claimed
